Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products. The Food and Drug Administration on Monday ...

Merck draws attention as healthcare strength, pharma activity, and defensive market rotation place large drugmakers back in ...

Merck shares were down on Thursday after sales of two of its most important products fell short of Wall Street estimates. Sales of Merck’s aging megablockbuster Keytruda were $8.1 billion in the third ...

Merck remains in focus after important pipeline developments, new product approvals, and clinical progress strengthen ...

Merck & Co., Inc. (NYSE:MRK) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors. On June 24, ...

Feb 1 (Reuters) - Merck & Co (MRK.N), opens new tab on Thursday said it was in the market for deals of up to around $15 billion as it plans for a loss of revenue from its aging cancer immunotherapy ...

Merck & Co. Inc. (NYSE:MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings ...

With a market cap of $258 billion, Merck & Co., Inc. (MRK) is a global healthcare company, operating in the pharmaceutical and animal health sectors. Based in Rahway, New Jersey, Merck develops ...

table { width: 100%; border-collapse: collapse; font-family: Arial, sans-serif; font-size: 14px; } th, td { padding: 8px; text-align: left; } th { background-color ...

During periods of uncertainty, investors often pay closer attention to businesses that look built to withstand the noise. When volatility picks up, the focus tends to shift toward companies with more ...